🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

953 results for “injection” Clear

  1. Adtralza 150 mg solution for injection in pre-filled syringe, The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP.

    LEO Pharma A/S

    Treatment of moderate-to-severe Atopic dermatitis

    phase 3 small molecule active

    1 trial

  2. Afinitor 10 mg tablets, Aromasin 25 mg coated tablets, Faslodex 250 mg solution for injection., Afinitor 5 mg tablets

    Pfizer Australia Pty Ltd

    Hormone receptor-positive, her2-negative advanced/metastatic breast cancer

    phase 3 small molecule active

    1 trial

  3. Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Retinal Vein Occlusion

    phase 3 mab completed

    1 trial

  4. Amvuttra 25 mg solution for injection in pre-filled syringe

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  5. Amvuttra 25 mg solution for injection in pre-filled syringe, Onpattro 2 mg/mL concentrate for solution for infusion.

    Alnylam Netherlands B.V.

    Hereditary Transthyretin Amyloidosis

    phase 3 small molecule active

    1 trial

  6. Amyvid 1900 MBq/mL solution for injection, VIZAMYL 400 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection, VIZAMYL 400 MBq/mL solution for injection, Trontinemab, Placebo Trontinemab, Amyvid 800 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, Amyvid 1900 MBq/mL solution for injection, [18F]MK-6240

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)

    phase 3 small molecule active

    1 trial

  7. An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria

    Lacuna Pharma Pty Ltd

    Primary Hyperoxaluria

    phase 3 other active

    1 trial

  8. Anifrolumab, Matching placebo solution for injection in aPFS; 0.8 mL fill volume

    AstraZeneca AB

    Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  9. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  10. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted), Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  11. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  12. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  13. Autologous Peripheral Blood Stem Cell injection

    Hospital Authority, Hong Kong

    Acute Myocardial Infarction

    phase 3 mab active

    1 trial

  14. Azacitidin Zentiva 25 mg/ml Pulver zur Herstellung einer Injektionssuspension, Azacitidine 25 mg/mL powder for suspension for injection, SY-1425, Placebo for Tamibarotene (SY-1425), AZACITIDINE

    Lacuna Pharma Pty Ltd

    Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  15. Azacitidine, Cedazuridine, Azacitidine, Vidaza 25 mg/ml powder for suspension for injection, Azacitidine, Cedazuridine

    Taiho Pharma Netherlands B.V.

    Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)

    phase 3 small molecule active

    1 trial

  16. BAT5906 injection

    Bio-Thera Solutions

    Diabetic Macular Edema (DME)

    phase 3 small molecule active

    1 trial

  17. BELZUPACAP SAROTALOCAN, Placebo (Sham injection) to Belzupacap Sarotalocan solution for sham injection 0.0 mg/mL, BELZUPACAP SAROTALOCAN

    Aura Biosciences

    Primary Indeterminate Lesions or Small Choroidal Melanoma

    phase 3 small molecule active

    1 trial

  18. BHV-8000, DaTSCAN 74 MBq/ml solution for injection, DaTSCAN 74 MBq/ml solution for injection, BHV-8000, Placebo for BHV-8000

    Biohaven Bioscience Ireland Limited

    Early Parkinson’s Disease

    phase 3 small molecule active

    1 trial

  19. BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient., BIIB059

    Biogen

    Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  20. BIIB059, BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient

    Biogen

    systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  21. BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient

    Biogen

    systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  22. BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient.

    Biogen

    Systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  23. BIIB067, PL1, Solution for injection, Intrathecal use. [Placebo]

    Biogen

    Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutation

    phase 3 small molecule active

    1 trial

  24. BMN 333, Voxzogo 0.56 mg powder and solvent for solution for injection, Voxzogo 1.2 mg powder and solvent for solution for injection, BMN 333

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources